|
Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC). |
|
|
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics |
|
Consulting or Advisory Role - Fortis; Janssen Oncology |
Research Funding - Janssen (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Janssen |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Janssen Oncology (Inst); Sanofi (Inst) |
|
|
Honoraria - Clovis Oncology; Novartis |
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; Janssen-Cilag; Pfizer |
Speakers' Bureau - Pfizer |
Research Funding - Sanofi/Aventis (Inst) |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Merck; Novartis; Pfizer |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Merck; Novartis; Pfizer |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Eisai; Merck; Novartis; Pfizer |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Lightpoint Medical |
Research Funding - Astellas Pharma; Bristol-Myers Squibb; German Cancer Aid; German Research Foundation; Janssen; Profound Medical |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen |
|
|
Honoraria - Astellas Medivation; Bayer; Janssen Oncology |
Consulting or Advisory Role - Exelixis |
Research Funding - Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst) |
Patents, Royalties, Other Intellectual Property - Oncoresponse: Exceptional responders |
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Merck Sharp & Dohme |
|
|
Honoraria - Bayer; Janssen; Sanofi |
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Janssen |
Research Funding - Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen (Inst); Pfizer (Inst); Tokai Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Bayer; Ipsen; Janssen |
|
|
Stock and Other Ownership Interests - Xing Technologies |
Honoraria - Ipsen; Janssen Oncology; Medivation/Astellas; Merck; Novartis; Pfizer; Roche/Genentech |
Consulting or Advisory Role - Pfizer |
Speakers' Bureau - Ipsen; Janssen Oncology; Medivation/Astellas; Merck; Novartis; Pfizer; Roche/Genentech |
Research Funding - Merck KGaA |
Patents, Royalties, Other Intellectual Property - 4 patents on nanotechnology |
Travel, Accommodations, Expenses - Ipsen; Janssen Oncology; Medivation/Astellas; Merck; Novartis; Pfizer; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Bayer; Daiichi Sankyo; Janssen; MSD; Sanofi; Takeda |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen; Takeda |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen; Sanofi; Takeda |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Employment - Janssen Research & Development |
|
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
Travel, Accommodations, Expenses - Johnson & Johnson |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Consulting or Advisory Role - Amgen; Bayer; Janssen Oncology; Pfizer |
Research Funding - Bayer (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst) |